Finally, the results raise the question of whether interventions that are already guideline-endorsed for cardiovascular and renal protection, such as SGLT2 inhibitors, renin-angiotensin system blockade, and comprehensive heart-failure therapies, can deliver measurable improvements in KCCQ scores when applied specifically in hypertensive diabetics. The gene discussed is REN; the disease is heart failure.